E2F1 and familial pancreatic carcinoma: Additionally, gemcitabine also promotes the expression of the ribonucleotide reductase M2 (RRM2) subunit in pancreatic cancer cells through the ERK/E2F1 pathway, promoting deoxyribonucleotide biosynthesis and inhibiting gemcitabine-induced DNA damage [153, 154].